Solvias will provide analytical release testing services for the first genome-edited cell therapy, CASGEVY™, to treat sickle cell disease in patients aged 12 and older. The therapy has gained FDA approval and conditional approval from the EMA for severe sickle cell disease and transfusion-dependent beta thalassemia treatments.
Seema Verma is ‘excited about progress’ of Oracle’s EHR modernization at VA
Seema Verma from Oracle Health updated on the VA’s Electronic Health Records Modernization at HIMSS25, highlighting increased patient satisfaction and ongoing challenges, including recent outages.
